Christine Tadgell new board member in AroCell

Christine Tadgell has been elected as board member in AroCell AB (publ) at the Annual General Meeting on May 18, 2016

Christine Tadgell received a Bachelor of Science degree at Concordia University, Montreal, Quebec, Canada. She is currently Vice-President for the inVentiv Health European Commercial Group situated in London, UK. She has a background within the area of biopharmaceuticals and international experience from Europe and North America, as well as extensive experience of commercial strategy within the pharmaceutical industry.

-The competence within the board will be additionally reinforced by Christine Tadgells international experience and knowledge. Christine Tadgell will be a strong resource in the continued company development, states Jan Stålemark, AroCell CEO. 

For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706 926206

About AroCell AB (publ) AroCell is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell’s new technology is based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover (speed of cell division and cell death) and as a result TK1 can be detected in the blood with a simple laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see . AroCell (AROC) is listed at AktieTorget and has about 2 800 shareholders.

The News in English, pdf

The News in Swedish, pdf